跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Rivazin - Philippines FDA Drug Approval Details
Approvals
/
Philippines FDA
/
Rivazin
Approved
STANDARD
Rivazin
Icure Pharmaceutical Inc.
🇵🇭 Food and Drug Administration - Philippines
Approval Date
Jul 14, 2025
Approval ID
4c56bf6523302454
Company
Icure Pharmaceutical Inc.
Type
Standard
Approval Details
Approval Id
4c56bf6523302454
Drug Approval Philippines Name
Rivazin
Product Name
Rivazin
Registration Number
DR-XY47762
Brand Name
Rivazin
Generic Name
Rivastigmine
Dosage Form
Transdermal Patch
Dosage Strength
18 mg/10 cm2 (9.5mg/24 hours)
Manufacturer
Icure Pharmaceutical Inc.
Importer
Endure Medical, Inc.
Distributor
Endure Medical, Inc.
Company Detail Path
/organization/icure-pharmaceutical-inc
Issuance Date
02 March 2022
Expiry Date
02 March 2027
Classification
Prescription Drug (RX)
Active Ingredients
Approved
Quick Info
Agency
Philippines FDA
Country
🇵🇭
Approval Date
Jul 14, 2025
Approval ID
4c56bf6523302454
Type
Standard
Back to Philippines FDA Approvals